Sebastian Gensior

What is EcoR1 Capital? EcoR1 Capital, LLC is a San Francisco based, biotechnology dedicated investment manager founded by Oleg Nodelman. The management entity was organised in 2012 and began investing in 2013. It runs from 357 Tehama Street, in the South of Market district. It is a registered investment adviser

A companion note to our piece on sleeves takes the opposite cut. The sleeves note was about the boundary: how capital is segregated, and what a creditor can reach. This note is about the vehicle that sits beside the fund, why it exists, and the governance and economics that surround

The term "sleeve" appears in royalty financing documents in at least three distinct senses. They are not interchangeable. Each carries a different answer to the two questions that decide what a sleeve is worth: * Can a creditor of one sleeve reach the assets of another. * Has the cash

A royalty fund's pitch to a pharmaceutical finance function compresses three claims into a single sentence: monetisation is non-dilutive, it is off-credit, and it is good for the accounts. The first is almost always true. The second and third are true for one version of the

The week in numbers June 21 to 28, 2026: eight royalty-bearing license-outs, options, and collaborations (Antengene with K2 Therapeutics, Nuvectis with Haisco, Insilico with SK Biopharmaceuticals, Combotope with Boehringer Ingelheim, Abbisko with Lilly, Antares with Novartis, Ionis with Recordati, Elixirgen with Nippon Shinyaku), two signed acquisitions (AbbVie with

A mechanics walk-through of the royalty payment, from the shelf price to the wire and into the buyer's account, as of June 2026. A royalty deal is usually summarised in a single number. "Tiered double-digit on net sales." "Eight percent." "A

Hercules Capital. NYSE: HTGC. The largest non-bank venture lender in the United States, and as of June 2026 a royalty originator.

Aktis Oncology is a Boston radiopharmaceutical developer that did the opposite of last week's subject. Where Rallybio was hollowed into a shell and its one thin royalty ring-fenced into a contingent value right, Aktis spent 2024 and 2025 building a platform that big pharma paid to access,

A pharmaceutical royalty is a claim on protected sales. Strip away the science and the structuring and what a buyer is really pricing is a window: the years between launch and the day a generic or biosimilar can lawfully take the market. In the European Union, the instrument that sets

The rate quoted on a press release is a headline. What is actually paid is a function with arguments, and most of those arguments are drafted to move it. A royalty re-rates in two distinct places. The first is inside the underlying licence, where tiers, base adjustments, step-downs